8 Early Signs of Ovarian Cancer

From women who've experienced them.

 ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

HEALTHY LIVING Ovarian Cancer 8 Early Signs of Ovarian Cancer—Straight From Women Who've Experienced Them Surgery Amazon Shoppers Rely on These "Handy" Wipes for Keeping Their Body Clean While Recovering From Surgery Food These Are the Healthiest Takeout Options for Every Cuisine, According to Nutritionists Wellness The 8 Best Posture Correctors of 2022 Skin Conditions 11 Reasons Your Butt Itches—and What to Do About It Depression 8 Ways to Cope With Seasonal Affective Disorder Fitness The Best Bodyweight Exercises You Can Do at Home Digestive Health When Does Constipation Become an Emergency? Lung Conditions 3 Main Pneumonia Causes to Know, According to Doctors Nutrition 7 Reasons Raspberries Are So Good for You Follow Us Unsubscribe Health may receive compensation for some links to products and services in this email. Offers may be subject to change without notice. This email was sent to natgeo-2995.food@blogger.com  |  Was this email forwarded to you? Subscribe here Dotdash Meredith Corporation, 225 Liberty Street, 4th Floor, New York, NY 10281 ©2022. All Rights Reserved. Privacy Policy  |  Terms of Service

A new hope for Alzheimer's

Plus more health news |

Email not displaying correctly? View it in your browser.

A new drug shows promise for Alzheimer's By Alice Park Senior Health Correspondent Reporting on Alzheimer’s disease over past few decades has been both rewarding and heartbreaking. Hope for new treatments is often followed by disappointment when drugs don’t help patients as much as experts had hoped. But the latest glimmer of hope is getting major headlines today. The Japanese company Eisai reported at a conference last night that its drug lecanemab helped people with mild-to-moderate Alzheimer’s disease slow their cognitive decline by 27% compared to people who took a placebo. Even better, the effect increased over time. It's not an enormous improvement, but it's better than anything currently available. Here are the three most important things to know: Lecanemab works by targeting amyloid, a protein that builds up in the brain during Alzheimer’s and eventually damages neurons. Other amyloid-based drugs—including the only approved treatment for the disease, aducanumab (or Aduhelm)—haven't been very effective. At the same conference, Roche reported that its anti-amyloid compound did not reduce amyloid enough to slow down progression of Alzheimer’s to a significant extent. The drug comes with potential side effects, including inflammation in the brain and bleeding for those also taking anticoagulant drugs. Doctors say the inflammation is manageable if patients are monitored carefully and that the bleeding risk needs further study. Eisai has filed for accelerated approval of the drug, and the U.S. Food and Drug Administration is expected to make a decision by early January. READ THE STORY.   Share the story

What else to read Many Asthma Patients Don't Follow Their Medication Plans. Here's How to Change That By Markham Heid A look at the latest measures to improve adherence, including new technologies and refinements to provider-patient interactions. Read More » How Israel Became the Global Center For Alternative Meat Tech By Aryn Baker / Tel Aviv, Israel Israel has become the center of lab-grown meat and alternative protein technologies, thanks to its geopolitics, climate, and culture. Read More » How the Pandemic Affected U.S. Birth Rates—and What Comes Next By Melissa S. Kearney and Phillip Levine At first there was a bust, then there was a boom, and now U.S. birth rates are back on their long-term, downward trend. Read More » Air Pollution Is Linked to Stillbirths—Especially in Poorer Countries By Jeffrey Kluger A new study finds a connection between fine-particle air pollution and the rate of stillbirths in low- and middle-income countries. Read More » Why Zumba Is Insanely Good Exercise By Markham Heid It's a party and a workout. (Originally published in 2017.) Read More »

One Last Read The Dark Side of Hospice In theory, hospice care is unquestionably a good thing for society: dying with dignity, in as much comfort as possible, and with the ability to spend meaningful time with loved ones in one’s own home is surely better than languishing in the clinical setting of a hospital bed. But, as Ava Kofman writes in this deeply reported New Yorker story, it has become yet another part of the U.S. health care system that profiteers are exploiting for their own gain, with disregard to the patients (and their families) it was designed to help. Read More »

If you were forwarded this and want to sign up to receive it daily, click here. Today's newsletter was written by Alice Park and Elijah Wolfson and edited by Mandy Oaklander.

Want more from TIME? Sign up for our other newsletters. Subscribe to TIME

TIME may receive compensation for some links to products and services in this email. Offers may be subject to change without notice.   Connect with TIME via Facebook | Twitter | Newsletters       UNSUBSCRIBE     PRIVACY POLICY     YOUR CALIFORNIA PRIVACY RIGHTS   TIME Customer Service, P.O. Box 37508, Boone, IA 50037-0508   Questions? Contact health@time.com   Copyright © 2022 TIME USA, LLC. All rights reserved.

✉️ (Notification!) Your Cyber Monday Savings Ends Soon!

SALE ALERT: Special offer unlocked View this e-mail: Web

Get an Extra 50% Off! You may not see this price again, so make a mad dash to claim your special offer. Subscribe for Just $12! Claim Yours Now Get inspired with a full year of... • Destination guides detailing must-see spots on the water • Tempting seafood eateries to visit and easy coastal recipes to make at home • Mood boards and how-to decor ideas, bringing the seashore into your spaces Subscribe Now Cover price is $12.99 a copy. The Cyber Monday Sale ends 12/4/22 at 12 A.M. CST. This email is sent from an unmonitored mailbox, please do not reply. Email Opt-Out Privacy Policy - Your California Rights Manage Your Subscription Dotdash Meredith, 1716 Locust Street, Des Moines, IA 50309 © Copyright 2022. All Rights Reserved.